Zynerba Pharmaceuticals Inc. (ZYNE)
Symbol Info
Listed Symbol ZYNE
Name Zynerba Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $86,000
Latest Fiscal EPS $-2.67
Price Info
21 Day Moving Average $11.3195
21 Day EMA $11.474720
50 Day Moving Average $11.6618
50 Day EMA $11.517470
200 Day EMA $9.973960
200 Day Moving Average 8.683100
52 Week High $16.47
52 Week Low $2.75
52 Week Change $79.528700
Alpha -0.017723
Beta 4.8094
Standard Deviation 0.321530
R2 0.275342
Periods 49
Share Information
10 Day Average Volume 631,576
20 Day Average Volume 623,711
30 Day Average Volume 746,677
50 Day Average Volume 1,043,129
Outstanding Shares 23,198,010
Float Shares 21,061,484
Percent Float 90.79%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 155
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 3,275,446
Institute Holdings Percent 50.400000
Institute Sold Previous 3 Months 432,532
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,136,526
Price Change
7 Day Price Change $0.4899998
7 Day Percent Change 4.19%
21 Day Price Change $1.2299995
21 Day Percent Change 11.22%
30 Day Price Change $1.1999998
30 Day Percent Change 10.92%
Month To Date Price Change $1.5000
Month To Date Percent 14.03%
90 Day Price Change $-1.440001
90 Day Percent Change -10.56%
Quarter To Date $-1.360001
Quarter To Date Percent -10.04%
180 Day Price Change $7.090000
180 Day Percent Change 139.02%
200 Day Price Change $7.150000
200 Day Percent Change 141.87%
Year To Date $9.219999
Year To Date Percent 310.44%
Profile
Description Zynerba Pharmaceuticals Inc together with its subsidiary is a pharmaceutical company which is focused on developing and commercializing proprietary next generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates are ZYN001 and ZYN002. The company has initiated a clinical trial for both the product candidates.
Details
Issue Type CS
Market Cap $282,783,742
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 23,198,010
CEO Armando Anido
Employees 25
Last Audit UQ
Classification
CIK 0001621443
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 80 West Lancaster Avenue
Suite 300
Devon, PA 19333
Website http://www.zynerba.com
Facisimile
Telephone +1 484 581-7505
Email fickenscherj@zynerba.com
Key Ratios
Profitability
EBIT Margin -43,034.1
EBITDA Margin -42,902
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $86,000
Revenue Per Share $0.0037
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $193,410,503
Price To Sales 3,288.182900
Price To Free Cash -9.4
PE High Last 5 Years -
Price To Book 2.9
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 3.3
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 9.4
Leverage Ratio 1.1
Quick Ratio 9.2
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -48.56
Return On Equity -57.11
Return On Capital -59.11
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ZYNE
Zynerba Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.